Lilly/BI Eye Diabetes Leadership In Expansive Risk-Sharing Collaboration
This article was originally published in The Pink Sheet Daily
Executive Summary
The two drug makers will jointly develop four diabetes drugs: two oral agents from Boehringer Ingelheim and two basal insulin analogues from Lilly.